Lung Cancer
Conditions
Brief summary
To learn about the effects of the investigational drug NKTR-255 in combination with the standard drug durvalumab on locally advanced NSCLC when given after CRT.
Detailed description
Primary Objectives: 1. Estimate the level of lymphocyte restoration after administration of NKTR-255 concurrently with durvalumab after chemoradiation. Absolute lymphocyte will be obtained along with changes in levels of NK cells, CD4 T cells, CD8 T cells, and B cells from baseline. 2. Monitor the safety of NKTR-255, which includes treatment related grade 3+ radiation pneumonitis Secondary Objectives: 1. Estimate the Progression-free survival time distribution 2. Estimate the Overall survival time distribution Exploratory objectives: 1. Characterize pharmacokinetics of NKTR-255 and assess immunogenicity of NKTR-255 2. Characterize pharmacodynamic effects and changes in activation markers and proliferation of NK and CD8 T cells, and cytokine levels after administration of NKTR-255 in combination with Durvalumab 3. Assess the correlation between ctDNA and efficacy measurements
Interventions
DRUGNKTR-255
Given by IV (vein)
DRUGDurvalumab
Given by IV (vein)
Sponsors
M.D. Anderson Cancer Center
Nektar Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age 18 years or older 2. Histologic diagnosis of non-small cell lung cancer 3. Written consent obtained before initiation of any study-related procedures 4. Definitive cancer treatment intent 5. Absence of concurrent malignancies at other sites, except low risk prostate cancer and basal cell of the skin. Participants with prior cancers should not be receiving active cancer treatment within the past 3 months. Cancer survivors who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease for 1 year and who are deemed at low risk for recurrence are eligible for the study. 6. Adequate liver (AST, ALT, Alk Phos, and Tbili \<2 fold upper limit) and kidney function (Cr \< 2.5 limit of normal and Cr clearance \>30) 7. ECOG 0-2
Exclusion criteria
Subjects are to be excluded from the study if any of the following conditions apply: 1. HIV infection, cellular immune deficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies 2. Prior diagnosis of hepatitis B or C (unless anti-hepatitis C therapy has produced a sustained virologic response); 3. History of clinically significant autoimmune disease, Crohn's disease, ulcerative colitis, or inflammatory disease. 4. Serious concomitant disorder, including active systemic infection requiring treatment, as judged by the Investigator. 5. Known or suspected hypersensitivity to any component of the investigational product 6. Recurrent radiation to the treatment site 7. Prior major surgery within 4 weeks of enrollment from which the patient has not recovered 8. Other condition or prior therapy that, in the opinion of the Investigator, compromises the subject's welfare or may confound study results 9. Previous enrollment in this study 10. Pregnancy: a female subject defined as a WOCBP who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 11. Prior exposure to any anti-PD-1 or anti-PD-L1 antibody. 12. Patients must be capable of understanding and providing a written informed consent. 13. Patients with leukemias or lymphomas with T cell/histiocyte or NK cell rich component(s) and other variants not otherwise specified that contain high numbers of T or NK cells. 14. Evidence of clinically significant interstitial lung disease or active noninfectious pneumonitis during the course of chemoradiation that is unresolved to ≤ grade 1. 15. Patients with grade 4 toxicities during chemoradiation not resolved to grade ≤ 1 by the end of chemoradiation. 16. Prior exposure to IL-2 or IL-5.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival time distribution | through study completion; an average of 1 year |
Countries
United States
Contacts
CONTACTSteven H. Lin, MD
PRINCIPAL_INVESTIGATORSteven Lin, MD
M.D. Anderson Cancer Center
Outcome results
None listed